Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors -Pipeline Insights, 2017
[Report Updated: 30-05-2017]

Published by Delve Insight: 30 May 2017 | 85761
Related Topics: FDA

Sorry, this report is no longer available.

We may have other suitable reports available - try Searching for Proprotein
or contact our sales team for personal assistance: phone +44 (0)7887945155 or email pdb@bioportfolio.co.uk.

Introduction

DelveInsight’s, “Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors. DelveInsight’s Report also assesses the Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope

• The report provides competitive pipeline landscape of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors

• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information

• Coverage of the Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type

• The report reviews key players involved in the therapeutics development for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and also provide company profiling

• The report also gives the information of dormant and discontinued pipeline projects

• Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages

• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Delivery Time 48-72 Hours

Table of Contents
for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors -Pipeline Insights, 2017 [Report Updated: 30-05-2017]

List Of Tables
in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors -Pipeline Insights, 2017 [Report Updated: 30-05-2017]

• Number of Products under Development for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors by Therapy Area, 2017

• Number of Products under Development for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, 2017

• Number of Products under Development by Companies

• Comparative Analysis by Filed and Phase III Products, 2017

• Comparative Analysis Phase II Products, 2017

• Comparative Analysis Phase I and IND Filed Products, 2017

• Comparative Analysis Discovery and Pre-Clinical Stage Products, 2017

• Drug Candidates Profiles

• Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Assessment by Monotherapy Products

• Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Assessment by Combination Products

• Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Assessment by Route of Administration

• Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Assessment by Stage and Route of Administration

• Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Assessment by Molecule Type

• Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Assessment by Stage and Molecule Type

• Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Therapeutics – Discontinued Products

• Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Therapeutics – Dormant Products

• Products under Development by Companies, 2017

List Of Figures, Charts and Diagrams
in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors -Pipeline Insights, 2017 [Report Updated: 30-05-2017]

• Number of Products under Development for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors by Therapy Area, 2017

• Number of Products under Development for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, 2017

• Filed and Phase III Products, 2017

• Phase II Products, 2017

• Phase I and IND Filed Products, 2017

• Discovery and Pre-Clinical Stage Products, 2017

• Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Assessment by Monotherapy Products

• Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Assessment by Combination Products

• Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Assessment by Route of Administration

• Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Assessment by Stage and Route of Administration

• Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Assessment by Molecule Type

• Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Assessment by Stage and Molecule Type

Additional Details

Publisher

Delve Insight

Publisher Information

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.



We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Reference

85761 | DIMR2017577

Number of Pages

60

Report Format

PDF

Delve Insight Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Pipeline Review, H2 2018
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated...
23 Oct 2018 by Global Markets Direct USD $3,500 More Info
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Pipeline Review, H1 2018
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated...
24 Apr 2018 by Global Markets Direct USD $3,500 More Info
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor -Pipeline Insight, 2018
“Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor - Pipeline Insight, 2018” report by...
14 Feb 2018 by Delve Insight USD $1,250 More Info
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Pipeline Review, H2 2017
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated...
10 Oct 2017 by Global Markets Direct USD $3,500 More Info
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor -Pipeline Insights, 2017
DelveInsight’s, “Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor-Mechanism of action...
01 Sep 2017 by Delve Insight USD $1,250 More Info

This report is published by Delve Insight

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.

We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

We Stock...

  • 360i Research
  • 99Strategy
  • Allied Market Research
  • Asia Market Information & Development Co.
  • Azoth Analytics
  • BioInformant
  • Black Swan Analysis
  • Canadean
  • CBR Pharma Insights
  • CRI
  • Current Analysis
  • Current Partnering
  • Daedal Research
  • Data bridge
  • Delve Insight
  • DPI Research
  • FirstWord Pharma
  • Future Market Insights
  • GBI Research
  • Global Data
  • Global Markets Direct
  • Global Research and Data Services GRDS
  • GMR Data
  • HeyReport
  • HongChun
  • HTStec
  • ICD Research
  • iGATE Research
  • IMARC
  • Industry ARC
  • Inkwood Research
  • IQ4I
  • Jain PharmaBiotech
  • Kelly Scientific
  • La Merie
  • Lifescience Intellipedia
  • LP Information
  • Market Data Forecast
  • Market Research Future
  • Marketline
  • MarketsandMarkets
  • McDerson
  • MedMarket Diligence
  • Meticulous Research
  • MicroMarketMonitor
  • MIReports
  • Mordor Intelligence LLC
  • MP Advisors
  • Occams Business Research
  • Prof Research
  • Progressive Markets
  • ProGrow Pharma Partners
  • Renub
  • Research Impact
  • RNCOS
  • Rockville Research
  • S&P Consulting
  • StratisticsMRC
  • The Business Research Company
  • Triton Market Research
  • Venture Planning Group (VPG)